A multinational research team led by Columbia University and the La Jolla Institute for Immunology has identified a novel viral target that could help combat the global resurgence of measles.
New images of one of the brain’s fastest-acting proteins—the kainate receptor—are providing critical clues that may lead to targeted therapies for epilepsy and other brain disorders.
The most detailed analysis to date of CRISPR genome editing in human embryos finds a significant risk of chromosomal abnormalities when using the technique at the earliest stage of human development.
Coronaviruses are adept at mimicking human immune proteins called complement, which may allow the viruses to gain a foothold in our bodies and cause disease.
Columbia/NYSPI researchers are examining how millions of college students are addressing COVID-19 challenges, including academic/life plans, decision-making, substance use, and mental well-being.
Cardiovascular disease is the No. 1 cause of maternal mortality in the United States, but a new study suggests specialized cardio-obstetrics teams may improve outcomes.
New data from Columbia and other ECMO centers throughout the world show that more than 60% of severe COVID-19 patients who receive ECMO, a heart-lung life support machine, survive.
Using stem cells from pig fat, a team led by Columbia engineers grew anatomically precise jawbones, including associated cartilage, that successfully replaced the pig's temporomandibular joint (TMJ).
Columbia researchers have uncovered an array of new genes that cause stillbirth, significantly increasing the understanding of the genetic foundations of a common, but little studied, condition.